19 May Lakewood-Amedex Announces Its Novel Bisphospocin® Class Of Antimicrobials Kills Multidrug Resistant-Tuberculosis (MDR-TB) Strains In Fifteen Minutes
SARASOTA, Fla., May 19, 2015 /PRNewswire/ — Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven effective at killing multidrug-resistant (MDR) strains of Mycobacterium tuberculosis, the bacteria responsible for the chronic lung infection tuberculosis. Approximately one-third of the world’s population is infected by this bacteria, which is increasingly becoming resistant to the current five-drug cocktail used to treat these infections. This issue is sparking serious concern in world health organizations and medical communities as they no longer have an effective cure for many of these patients.
These studies expand on previously published experiments demonstrating Nu-3 to be effective in killing multi-drug resistant bacteria and highlight the potential of this important new class of antimicrobials. Specifically, the time-kill studies revealed that Nu-3 was highly effective, generating a 100 percent kill rate with as little as a 15-minute incubation against MDR-TB strains CSU 39 and CSU 41 – both of which are resistant to more than six classes of antibiotics – and wild type strain H37Rv.
This result highlights the novel directly bactericidal mechanism of action of the bisphosphocin class, which is time and concentration dependent, resulting in killing of gram positive and gram negative bacteria in less time than they take to replicate.
Lakewood-Amedex believes the bisphosphocin class of antimicrobials has the ability to significantly change how infections are treated and overcome the ability of bacteria to become resistant. In previously conducted studies published in a peer-reviewed journal, bisphosphocin Nu-3 was shown to eradicate a Pseudomonal lung infection with a single aerosolized dose. This result is significant because bisphosphocins can eradicate slow growing or stationary bacteria, such as Mycobacterium, eliminating any opportunity for the development of resistance. Based on this data, an aerosolized solo Nu-3 treatment would be expected to dramatically reduce the current tuberculosis treatment regime, which is composed of a five-drug cocktail administered for up to six months or longer if the strains are found to be MDR-TB or extensively drug-resistant (XDR).
The Company is developing Nu-3 as an intravenous formulation for serious bacterial infections, such as complicated urinary tract infections, and a topical formulation for difficult to treat infections, such as chronic infected diabetic foot ulcers, fungal infections, and ophthalmic infections where a broad spectrum of activity is required.
About Lakewood-Amedex Inc.
Lakewood-Amedex is a privately held clinical-stage biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds and orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer, influenza, and hepatitis. The Company’s products and technology are covered by an extensive patent portfolio consisting of over 70 granted and/or issued patents or pending patent applications filed on a worldwide basis covering all major pharmaceutical markets. The Company’s lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative, and antibiotic-resistant bacteria and is expected to enter the clinic in 2015.
This press release contains forward-looking statements that can be identified by terminology such as “expects”, “potential”, “suggests”, “may”, “will” or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are “forward-looking statements” that involve risk and uncertainties, which could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company’s planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.